Weight Loss Jabs Linked to Higher Risk of Eye Stroke, Study Finds
A new analysis has revealed that the weight-loss jab Wegovy may carry the highest risk of sudden sight loss, commonly referred to as an "eye stroke," when compared to similar medications such as Ozempic. The study, published in the British Journal of Ophthalmology, examined adverse event reports and found that men were three times more likely than women to experience this condition, known as ischaemic optic neuropathy (Ion).
Research Methodology and Key Findings
Researchers conducted a comprehensive analysis of over 30 million adverse event reports submitted to the U.S. Food and Drug Administration (FDA). Their investigation concluded that the risk of Ion appears to be dose and formulation dependent, with Wegovy showing the highest risk among the medications studied. Despite having fewer overall adverse event reports compared to Ozempic, the analysis indicated that the odds of developing Ion were almost five times higher with Wegovy.
Manufacturer's Response and Safety Measures
Novo Nordisk, the manufacturer of Wegovy, has responded to the findings by emphasising that patient safety is a top priority. The company has updated patient information leaflets to reflect the new data. However, Novo Nordisk maintains that there is no reasonable possibility of a causal link between their medication and the condition, asserting that the benefit-risk profile of Wegovy remains favourable for patients.
Implications for Patients and Healthcare Providers
This study highlights the importance of monitoring and reporting adverse effects associated with weight-loss medications. Healthcare providers are advised to consider these risks when prescribing such treatments, particularly for male patients who may be at higher risk. Patients using Wegovy or similar jabs should be aware of the potential symptoms of Ion, such as sudden vision loss, and seek immediate medical attention if they occur.
The findings underscore the need for ongoing research and vigilance in the use of pharmaceutical weight-loss solutions, balancing their benefits against potential health risks.
